UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October, 2023
Commission File Number 000-29962
Kazia Therapeutics Limited
(Translation of registrant’s name into English)
Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☑ Form 40-F ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
ASX and Nasdaq Trading Halt Extension
On October 10, 2023, Kazia Therapeutics Limited (the “Company”) requested an extension to the halt to the trading of the Company’s securities quoted on the Australian Securities Exchange (ASX) until October 11, 2023 in accordance with the Listing Rules of the ASX. The Company also requested an extension to the halt to the trading of the Company’s American Depositary Shares listed on the Nasdaq Capital Market until October 11, 2023 in accordance with the Nasdaq Listing Rules. The document is furnished herewith as Exhibit 99.1 to this report on Form 6-K.
EXHIBIT LIST
Exhibit | Description | |
99.1 | ASX Announcement of Kazia Therapeutics Limited dated October 10, 2023 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Kazia Therapeutics Limited (Registrant) |
/s/ Karen Krumeich |
Karen Krumeich |
Chief Financial Officer |
Date: October 10, 2023 |